These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 36622756

  • 41. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC, Lee YJ, Huang YT, Liao CH, Tsuji M, Hsueh PR.
    J Antimicrob Chemother; 2019 Feb 01; 74(2):380-386. PubMed ID: 30357343
    [Abstract] [Full Text] [Related]

  • 42. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
    Arca-Suárez J, Lasarte-Monterrubio C, Rodiño-Janeiro BK, Cabot G, Vázquez-Ucha JC, Rodríguez-Iglesias M, Galán-Sánchez F, Beceiro A, González-Bello C, Oliver A, Bou G.
    J Antimicrob Chemother; 2021 Jan 01; 76(1):91-100. PubMed ID: 33083833
    [Abstract] [Full Text] [Related]

  • 43. Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
    Gill CM, Nicolau DP, ERACE-PA Global Study Group.
    J Antimicrob Chemother; 2022 Dec 23; 78(1):252-256. PubMed ID: 36411249
    [Abstract] [Full Text] [Related]

  • 44. In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020.
    Karlowsky JA, Lob SH, Siddiqui F, Akrich B, DeRyke CA, Young K, Motyl MR, Hawser SP, Sahm DF.
    J Med Microbiol; 2023 Feb 23; 72(2):. PubMed ID: 36763081
    [Abstract] [Full Text] [Related]

  • 45. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
    Wi YM, Greenwood-Quaintance KE, Schuetz AN, Ko KS, Peck KR, Song JH, Patel R.
    Antimicrob Agents Chemother; 2018 Jan 23; 62(1):. PubMed ID: 29133568
    [Abstract] [Full Text] [Related]

  • 46. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
    Sid Ahmed MA, Abdel Hadi H, Hassan AAI, Abu Jarir S, Al-Maslamani MA, Eltai NO, Dousa KM, Hujer AM, Sultan AA, Soderquist B, Bonomo RA, Ibrahim EB, Jass J, Omrani AS.
    J Antimicrob Chemother; 2019 Dec 01; 74(12):3497-3504. PubMed ID: 31504587
    [Abstract] [Full Text] [Related]

  • 47. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
    Ruedas-López A, Alonso-García I, Lasarte-Monterrubio C, Guijarro-Sánchez P, Gato E, Vázquez-Ucha JC, Vallejo JA, Fraile-Ribot PA, Fernández-Pérez B, Velasco D, Gutiérrez-Urbón JM, Oviaño M, Beceiro A, González-Bello C, Oliver A, Arca-Suárez J, Bou G.
    Antimicrob Agents Chemother; 2022 Feb 15; 66(2):e0206721. PubMed ID: 34930034
    [Abstract] [Full Text] [Related]

  • 48. Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: Results from the study for monitoring antimicrobial resistance trends (SMART - Brazil; 2016-2017).
    Beirão EM, Rodrigues SDS, Andrade TK, Serra FB, Paula MDN, Polis TJB, Gales AC.
    Braz J Infect Dis; 2020 Feb 15; 24(4):310-321. PubMed ID: 32663440
    [Abstract] [Full Text] [Related]

  • 49. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016 and 2019 in China.
    Yu W, Zhang H, Zhu Y, Jia P, Xu Y, Yang Q.
    Int J Antimicrob Agents; 2023 Apr 15; 61(4):106741. PubMed ID: 36736928
    [Abstract] [Full Text] [Related]

  • 50. In vitro activity of imipenem/relebactam and ceftazidime/avibactam against carbapenem-resistant Klebsiella pneumoniae from blood cultures in a University hospital in Serbia.
    Zornic S, Petrovic I, Lukovic B.
    Acta Microbiol Immunol Hung; 2023 Sep 21; 70(3):187-192. PubMed ID: 37535440
    [Abstract] [Full Text] [Related]

  • 51. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2018 Jan 21; 78(1):65-98. PubMed ID: 29230684
    [Abstract] [Full Text] [Related]

  • 52. Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates-SMART United States 2019-21.
    Karlowsky JA, Lob SH, Bauer KA, Esterly J, Siddiqui F, Young K, Motyl MR, Sahm DF.
    JAC Antimicrob Resist; 2024 Feb 21; 6(1):dlad152. PubMed ID: 38222461
    [Abstract] [Full Text] [Related]

  • 53. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
    Karlowsky JA, Lob SH, Raddatz J, DePestel DD, Young K, Motyl MR, Sahm DF.
    Clin Infect Dis; 2021 Jun 15; 72(12):2112-2120. PubMed ID: 32246147
    [Abstract] [Full Text] [Related]

  • 54. Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New β-Lactam Combination Agents.
    Asempa TE, Nicolau DP, Kuti JL.
    J Clin Microbiol; 2019 Aug 15; 57(8):. PubMed ID: 31118271
    [Abstract] [Full Text] [Related]

  • 55. Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018).
    Cantón R, Loza E, Arcay RM, Cercenado E, Castillo FJ, Cisterna R, Gálvez-Benítez L, González Romo F, Hernández-Cabezas A, Rodríguez-Lozano J, Suárez-Barrenechea AI, Tubau F, Díaz-Regañón J, López-Mendoza D, SMART-Spain Working Group.
    Rev Esp Quimioter; 2021 Jun 15; 34(3):228-237. PubMed ID: 33645948
    [Abstract] [Full Text] [Related]

  • 56. In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam.
    Rubio AM, Kline EG, Jones CE, Chen L, Kreiswirth BN, Nguyen MH, Clancy CJ, Cooper VS, Haidar G, Van Tyne D, Shields RK.
    Antimicrob Agents Chemother; 2021 May 18; 65(6):. PubMed ID: 33820773
    [Abstract] [Full Text] [Related]

  • 57. Susceptibility of Gram-negative pathogens collected in Israel to ceftolozane/tazobactam, imipenem/relebactam and comparators: SMART 2018-22.
    Wise MG, DeRyke CA, Alekseeva I, Siddiqui F, Young K, Motyl MR, Sahm DF.
    JAC Antimicrob Resist; 2024 Oct 18; 6(5):dlae150. PubMed ID: 39291180
    [Abstract] [Full Text] [Related]

  • 58. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN.
    J Antimicrob Chemother; 2014 Oct 18; 69(10):2713-22. PubMed ID: 24917579
    [Abstract] [Full Text] [Related]

  • 59. In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae.
    Findlay J, Rens C, Poirel L, Nordmann P.
    Antimicrob Agents Chemother; 2022 Oct 18; 66(10):e0091822. PubMed ID: 36154170
    [Abstract] [Full Text] [Related]

  • 60. Integrated Genome-Wide Analysis of an Isogenic Pair of Pseudomonas aeruginosa Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Piperacillin/Tazobactam.
    Huang W, Hamouche JE, Wang G, Smith M, Yin C, Dhand A, Dimitrova N, Fallon JT.
    Int J Mol Sci; 2020 Feb 04; 21(3):. PubMed ID: 32033143
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.